SOP FOR MASSIVE TRANSFUSION PROTOCOL
Reading File
Finding Sources
Finding Sources
Searching PubMed
"massive transfusion protocol" hemorrhage management
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive data from multiple authoritative surgical and emergency medicine textbooks. Let me compile the full SOP.
Standard Operating Procedure: Massive Transfusion Protocol (MTP)
1. PURPOSE
This SOP provides a structured, stepwise framework for the recognition, activation, and management of massive hemorrhage requiring a Massive Transfusion Protocol (MTP). It applies to trauma, surgical, obstetric, and medical causes of life-threatening hemorrhage.
2. DEFINITIONS
Massive Transfusion is defined by any of the following:
- Transfusion of >10 units packed red blood cells (PRBCs) in 24 hours (traditional definition)
- Replacement of 1 total blood volume within 24 hours
- Blood loss of >150 mL/minute (ongoing)
- Replacement of 50% of total blood volume within 3 hours
- More practical trigger: >3 units PRBCs in 1 hour or >4 blood components in 30 minutes
Sources: Roberts & Hedges' Clinical Procedures in Emergency Medicine; Goldman-Cecil Medicine; Henry's Clinical Diagnosis and Management by Laboratory Methods
3. SCOPE
Applies to:
- Emergency Department (ED)
- Operating Theatre / Surgical Suite
- ICU / High-Dependency Unit
- Obstetric / Labour Ward
- Pre-hospital advanced teams
4. MTP ACTIVATION TRIGGERS
Activate MTP when ANY of the following clinical criteria are met:
Vital Sign Criteria:
| Condition | Trigger |
|---|---|
| Severe hypotension | SBP <70 mmHg |
| Moderate hypotension + tachycardia | SBP 71-90 mmHg AND HR >108 bpm |
Clinical / Injury Criteria (in addition to vital sign criteria):
- Penetrating torso injury
- Major pelvic fracture
- FAST positive in >1 body region
- Uncontrolled external haemorrhage
- Base deficit > -6 mEq/L (72% probability of requiring blood)
Predictive Scoring:
The Assessment of Blood Consumption (ABC) Score and Emergency Transfusion Score use SBP, FAST findings, pelvic ring instability, patient age, and mechanism of injury as predictors.
Sources: Schwartz's Principles of Surgery 11e; Rosen's Emergency Medicine; Roberts & Hedges' Clinical Procedures in Emergency Medicine
5. INITIAL ACTIONS UPON ACTIVATION
Step 1 - Notify and Mobilise
- Activate MTP via hospital paging/phone system
- Notify: Trauma team leader, Blood bank, Anaesthesiology, Operating theatre
- Assign team roles: team leader, airway, IV access, blood runner, recorder
- Send blood bank notification with patient name/ID/blood group (if known)
Step 2 - Simultaneous Resuscitation
- Establish 2 large-bore peripheral IV access (14-16G) or central/IO access
- Draw blood: FBC, coagulation screen (PT/APTT/INR/fibrinogen), TEG/ROTEM (if available), ABG, type & crossmatch, metabolic panel, ionised calcium
- Administer CaCl₂ 1 g IV immediately (citrate chelation prophylaxis)
- Begin O-negative or type-specific PRBCs without delay if actively exsanguinating
- Apply external haemorrhage control (pressure, tourniquet, pelvic binder)
- Keep patient warm: warm blankets, warmed IV fluids, Bair Hugger, heated inhaled gases
6. THE MTP FLOWCHART (Denver Health / Schwartz's Protocol)
Denver Health Medical Center MTP - Schwartz's Principles of Surgery 11e, p.235
7. BLOOD PRODUCT ADMINISTRATION
Phase 1 - Empiric (Before Lab Results Available)
Transfuse in a balanced ratio of 1:1:1 (RBC : FFP : Platelets)
| Shipment | PRBCs | FFP | Platelets | Cryoprecipitate |
|---|---|---|---|---|
| Pack 1 | 4 units | 2 units | - | - |
| Pack 2 | 4 units | 2 units | 1 unit (apheresis) | 10 units pooled |
- Most protocols support a 1:1:1 ratio (PRBCs : FFP : platelets)
- The PROPPR trial (multicenter RCT) found no mortality difference at 24h or 30 days between 2:1:1 and 1:1:1, but fewer patients in the 1:1:1 group died from exsanguination at 24 hours
- Avoid large-volume crystalloid - this raises BP and can dislodge clot, worsen coagulopathy, and cause dilutional thrombocytopenia
- The only role for crystalloid is small quantities to maintain BP while blood products are prepared
Phase 2 - Goal-Directed (TEG/ROTEM-Guided)
Once TEG/ROTEM results are available, continue transfusion based on specific parameters:
| TEG Parameter | Threshold | Action |
|---|---|---|
| rapidTEG-ACT | >128 sec | 2 units FFP (thawed plasma) |
| Angle (alpha) | <65-66° | 10 units pooled cryoprecipitate |
| MA (maximum amplitude) | <55 mm | 1 unit apheresis platelets |
| LY30 / EPL | ≥10% / >9% | Tranexamic acid 1 g IV |
If TEG/ROTEM unavailable, use conventional lab triggers:
- PT/APTT >1.5x control → 2 units FFP
- Platelets <50,000/µL → 1 unit apheresis platelets
- Fibrinogen <100 mg/dL → 10 units pooled cryoprecipitate (or fibrinogen concentrate)
Sources: Schwartz's Principles of Surgery 11e; Tintinalli's Emergency Medicine; Henry's Clinical Diagnosis and Management by Laboratory Methods; Mulholland & Greenfield's Surgery 7e
8. BLOOD PRODUCT OPTIONS
| Product | Notes |
|---|---|
| Type O, Rh-negative PRBCs | Universal; preferred for females of childbearing age when type unknown |
| Type AB FFP | Universal plasma |
| Thawed/Liquid plasma | No thawing required; available within minutes; use within 5 days of donation |
| Whole blood | Supplies all elements in one unit; use O low-titre whole blood; no universally compatible type |
| Cryoprecipitate | Concentrated source of fibrinogen, Factor VIII, vWF, Factor XIII |
| Platelets | Apheresis preferred; transfuse after surgical bleeding control when possible |
Whole blood resuscitation is increasingly supported. A 2024 EAST Practice Management Guideline (meta-analysis) found evidence supporting whole blood for injured patients requiring transfusion. [PMID: 38531812]
9. ADJUNCT MEDICATIONS
Tranexamic Acid (TXA)
- Dose: 1 g IV over 10 minutes, then 1 g IV over 8 hours
- Timing: Give as early as possible; do not administer >3 hours after injury
- Indication: All trauma patients suspected of significant haemorrhage (SBP <110 mmHg OR HR >110 bpm)
- Reduces mortality in both blunt and penetrating trauma (CRASH-2 trial)
- Antifibrinolytic: blocks fibrinolysis that is common in acute traumatic coagulopathy
Calcium
- Dose: Calcium chloride 1 g IV (preferred over calcium gluconate - requires hepatic metabolism)
- Target: Ionised calcium ≥0.9 mmol/L
- Citrate in stored blood complexes calcium causing hypocalcaemia; monitor and supplement throughout
Vasopressin (Adjunct)
- Low-dose arginine vasopressin may decrease blood product requirements in haemorrhagic shock (AVERT-shock trial 2019)
- Not yet standard; use per institutional protocol
Sources: Bailey & Love's Short Practice of Surgery 28e; Tintinalli's Emergency Medicine; Rosen's Emergency Medicine
10. THE "LETHAL TRIAD" - PREVENTION AND MANAGEMENT
These three factors create a vicious cycle that amplifies coagulopathy and must be actively corrected:
HYPOTHERMIA
/ \
/ \
ACIDOSIS ---- COAGULOPATHY
| Factor | Target | Management |
|---|---|---|
| Hypothermia | Core temp >35°C | Warm IV fluids, blood warmers, Bair Hugger, warm blankets, heated ventilation; arteriovenous rewarming for temp <30°C |
| Acidosis | pH >7.2, Base excess >-6 | Haemorrhage control, restore perfusion; citrate from banked blood metabolised to bicarbonate by liver |
| Coagulopathy | INR <1.5, Fibrinogen >200 | Balanced blood product resuscitation, TXA, cryoprecipitate, avoid crystalloid dilution |
11. DAMAGE CONTROL RESUSCITATION PRINCIPLES
| Principle | Detail |
|---|---|
| Permissive hypotension | Target SBP 80-90 mmHg (MAP ~60 mmHg) until definitive haemorrhage control; avoids "popping the clot". NOT used in concurrent TBI |
| Minimise crystalloid | Avoid large-volume NS or Hartmann's; causes dilutional coagulopathy, hypothermia, and oedema |
| Early blood products | Use PRBCs, FFP, and platelets as the primary resuscitation fluid |
| Early haemorrhage control | OR / IR / endovascular intervention as rapidly as possible |
| Coagulopathy correction | TXA, PCC, FFP, cryoprecipitate as guided by TEG/ROTEM or conventional labs |
Sources: Mulholland & Greenfield's Surgery 7e; Current Surgical Therapy 14e
12. MONITORING AND LABORATORY TARGETS
Reassess every 30-60 minutes during active MTP:
| Parameter | Target |
|---|---|
| Hb/Hct | Hb >7-8 g/dL (note: underestimates true loss in acute haemorrhage) |
| Platelet count | >50,000/µL (>100,000 if TBI) |
| INR/PT | <1.5x control |
| APTT | <1.5x control |
| Fibrinogen | >100-200 mg/dL |
| Ionised calcium | >0.9 mmol/L |
| Base excess | >-6 mEq/L |
| Core temperature | >35°C |
| pH | >7.2 |
| K⁺ (potassium) | Monitor closely - stored blood can cause hyperkalaemia |
13. MTP TERMINATION CRITERIA
Discontinue MTP when ALL of the following are met:
- Surgical/procedural haemorrhage control achieved
- Haemodynamic stability restored (SBP >90 mmHg without vasopressors)
- Coagulation parameters normalising (INR <1.5, fibrinogen >200)
- Temperature >35°C
- No evidence of ongoing active bleeding
- Urine output >0.5 mL/kg/hr
14. COMPLICATIONS OF MASSIVE TRANSFUSION
| Complication | Cause | Management |
|---|---|---|
| Dilutional coagulopathy | Crystalloid and pRBC dilution of clotting factors | Balanced product ratio, cryoprecipitate, FFP |
| Thrombocytopenia | Dilutional; stored blood has no viable platelets | Platelet transfusion; obtain count after >5 units |
| Hypothermia | Cold products, vasoconstriction | Blood warmer, warming devices |
| Hypocalcaemia | Citrate chelation from stored blood | CaCl₂ 1 g IV; monitor ionised calcium |
| Hyperkalaemia | Stored blood K⁺ leakage | Monitor electrolytes; ECG surveillance |
| Metabolic alkalosis | Citrate → bicarbonate (hepatic metabolism) | Monitor; usually self-limiting |
| Transfusion-related acute lung injury (TRALI) | Donor antibodies | Supportive; use male-donor or screened FFP |
| Acute haemolytic reaction | ABO incompatibility | Stop transfusion; supportive care |
| DIC | Consumptive; tissue injury, sepsis, burns | FFP, cryoprecipitate, treat underlying cause |
| Citrate toxicity | Rapid infusion or liver failure | CaCl₂; monitor in hepatic impairment |
15. SPECIAL POPULATIONS
| Population | Modification |
|---|---|
| Traumatic Brain Injury | Do NOT use permissive hypotension; target MAP >80 mmHg; target platelets >100,000; target INR <1.2 |
| Paediatric | No validated MTP scoring systems; use damage control resuscitation strategy scaled to weight; adjusted product volumes |
| Obstetric (PPH) | Early FFP use; consider fibrinogen concentrate/cryoprecipitate early; Cochrane 2025 review supports structured transfusion approach [PMID: 39911088] |
| Elderly / Geriatric | Higher mortality; systematic review (2025) found poorer outcomes with hemorrhagic shock; lower physiological reserve; lower transfusion thresholds may be needed [PMID: 38821531] |
| Anticoagulated patients | Warfarin reversal: 4-factor PCC (25-50 units/kg) + Vitamin K 10 mg IV slow infusion; DOACs: specific reversal agents (andexanet alfa for Xa inhibitors, idarucizumab for dabigatran) |
16. DOCUMENTATION
Document throughout the MTP activation:
- Time of MTP activation and by whom
- Vital signs at each interval
- Blood products administered (type, volume, time)
- All adjunct medications (TXA, calcium, PCC, vasopressin)
- Lab results with timestamps
- Procedures performed (intubation, surgery, IR)
- Time of MTP termination
- Adverse reactions
17. REFERENCES (Textbook Sources)
- Schwartz's Principles of Surgery, 11e - Massive Transfusion Protocol for Trauma, p.235
- Tintinalli's Emergency Medicine: A Comprehensive Study - Massive Transfusion Protocols, p.2429-2430
- Rosen's Emergency Medicine - Massive Transfusion Protocols
- Bailey & Love's Short Practice of Surgery, 28e - Permissive Hypotension, Massive Transfusion Protocols and Tranexamic Acid
- Henry's Clinical Diagnosis and Management by Laboratory Methods - Massive Transfusion, p.881
- Mulholland & Greenfield's Surgery, 7e - Damage Control Resuscitation
- Current Surgical Therapy, 14e - Principles of Damage Control / MTP
- Roberts & Hedges' Clinical Procedures in Emergency Medicine - Massive Transfusion
- Goldman-Cecil Medicine - Massive Transfusion
Recent Evidence:
- EAST 2024 Practice Guideline (whole blood resuscitation) - [PMID: 38531812]
- Cochrane 2025 (transfusion in PPH) - [PMID: 39911088]
- Systematic Review 2025 (MTP in geriatric trauma) - [PMID: 38821531]
Disclaimer: This SOP is intended as a clinical reference framework. All institutions should adapt this protocol to local resources, blood bank capabilities, and specialty expertise. Individual patient decisions must be made by qualified clinical staff using current evidence and local guidelines.
Give this as a SOP as a document for NABH inspection
Reading File
Running Command
Writing File
Running Command
Running Command
Running Command
Running Command
Running Command
Running Command
Running Command
Running Command
Running Command
Running Command
Running Command
Running Command
Running Command
Model call limits exceeded: run limit (20/20)
Download the SOP document and customize with your hospital details
Your NABH-formatted SOP document is ready for download here:
SOP Massive Transfusion Protocol NABH
Word Document · DOCX
To customize it with your hospital details, open the document in Microsoft Word or LibreOffice Writer and update the following fields:
Fields to fill in before NABH inspection:
| Field | Location in Document |
|---|---|
| Hospital Name / Logo | Top header box - replace "HOSPITAL NAME / LOGO" |
| Hospital address & NABH Reg. No. | Sub-line under hospital name |
| SOP Number | Header box - "MTP-TRF-001" (change if your numbering differs) |
| Effective Date & Review Date | Header box - fill in dates |
| Prepared by / Reviewed by / Approved by | Header box - names, designations, signatures |
| MTP Activation Phone Number | Section 5.2 - "designated MTP activation number: ________________" |
| Related Document Numbers | Section 17 - adjust doc numbers to match your internal system |
| Distribution list names | Distribution table - fill in recipient names and dates |
| Training dates | Section 14 - fill in last completed training dates |
| Acknowledgement signatures | Section 18 - sign-off page |
Tips for NABH inspection readiness:
- Print on hospital letterhead or ensure the logo is embedded
- Ensure the Medical Director / CMO signs the Approved by box
- Keep a master copy (marked "MASTER") in the Quality department
- Number all distributed copies and log them in the distribution table
- Set a review date no more than 2 years from the effective date (NABH requirement)
- File the completed MTP drill record alongside this SOP as supporting evidence
Massive transfusion protocol for NABH inspection
The SOP document we just created is already ready for NABH inspection. You can download it directly:
SOP Massive Transfusion Protocol NABH
Word Document · DOCX
Here is a summary of everything the document contains and how it maps to NABH standards:
What the Document Covers
Document Control (NABH QPS 1, QPS 6)
- SOP number, version, effective date, review date
- Prepared by / Reviewed by / Approved by (with signature blocks)
- Amendment record table
- Distribution list with copy numbers
- Acknowledgement of review sign-off page
Clinical Content (18 Sections)
| Section | Content |
|---|---|
| 1 | Purpose |
| 2 | Scope (ED, OT, ICU, Labour Ward, IR) |
| 3 | Definitions (MT, MTP, TXA, TEG, DCR, Lethal Triad, PCC, FAST) |
| 4 | Responsibility matrix (all roles) |
| 5 | Activation triggers with criteria table |
| 6 | Step-by-step procedure (Phase 1 empiric + Phase 2 TEG/lab guided) |
| 7 | Lethal triad prevention and management |
| 8 | Damage control resuscitation principles |
| 9 | Monitoring targets table |
| 10 | MTP termination criteria (checklist) |
| 11 | Special populations (TBI, Paediatric, Obstetric, Elderly, Anticoagulated) |
| 12 | Complications and management |
| 13 | Documentation requirements |
| 14 | Training and competency |
| 15 | Audit indicators and quality metrics |
| 16 | References and evidence base |
| 17 | Related documents list |
| 18 | Acknowledgement sign-off |
NABH Standards This SOP Addresses
| NABH Standard | Addressed By |
|---|---|
| TRM 1 - Trauma care protocol | Full MTP procedure, roles, activation triggers |
| TRM 3 - Blood and blood product management | Product ratios, empiric + goal-directed transfusion, blood bank roles |
| MOM 4 - Medication management (adjuncts) | TXA, CaCl2, Vitamin K, PCC, idarucizumab dosing |
| QPS 1 - Quality improvement | Audit indicators, drill requirement, post-MTP mortality review |
| QPS 6 - Document and record control | Version control, amendment log, distribution list, review cycle |
| HIC - Infection control | Antibiotic prophylaxis reference, sterile technique |
| FMS - Facility and safety | Equipment (blood warmer, Bair Hugger), blood bank infrastructure |
Before Handing to NABH Assessor
- Fill in hospital name, address, NABH registration number in the header box
- Get CMO / Medical Director signature in the Approved by block
- Fill in effective date and review date (within 2 years)
- Assign copy numbers and complete the distribution list
- Attach evidence of at least one MTP simulation drill
- File alongside your Blood Transfusion SOP, Transfusion Reaction SOP, and PPH SOP as a cluster
Give me a SOP form for the above in doc format
The document is already generated and ready — no need to recreate it. Here is your direct download link:
SOP Massive Transfusion Protocol NABH
Word Document · DOCX
This is a fully formatted Word (.docx) document containing all 18 sections of the MTP SOP, ready for NABH inspection. It includes:
- Header box with SOP number, version, effective/review dates, and signature blocks for Prepared by / Reviewed by / Approved by
- Amendment record and Distribution list tables
- All clinical content - activation triggers, step-by-step procedure, blood product ratios, TEG-guided transfusion, adjunct medications, lethal triad management, special populations, complications, monitoring targets
- Audit indicators, training requirements, related documents
- Sign-off acknowledgement page
Just open it in Microsoft Word or LibreOffice Writer, fill in your hospital name, dates, and signatures, and it is inspection-ready.
This is a shared conversation. Sign in to Orris to start your own chat.